A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

The United Kingdom's health regulator is investigating weight loss jabs like Ozempic and Mounjaro after linking it to ...

Patients with type 2 diabetes had a lower risk of glaucoma when they used glucagon-like peptide 1 (GLP-1) receptor agonists ...

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...

Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 ...

Viking Therapeutics initiates VANQUISH phase 3 obesity clinical programme with GLP-1/GIP agonist VK2735: San Diego Thursday, June 26, 2025, 10:00 Hrs [IST] Viking Therapeutics, In ...

WHO is alerting health-care professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicines—Ozempic, ...

Wegovy will be available in a once-weekly innovative pen device in five dose strengths – 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and a ...